Authors
Latest:
A physician’s advice for defusing patient angerRebekah Bernard, MD, provides tips for improving interactions with patients who are angry.
Latest:
Urology Practice advice: prioritize billing and coding oversightWhen a miscoded procedure is the result of substantial negligence or fraud, it can be detrimental to a medical practice or physician.
Latest:
Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancerTim A. Richardson, MD, outlines the 2 key scenarios for utilizing genetic testing in clinical practice.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Urologic Consultants has joined Solaris HealthLeading West Michigan practice now affiliated with nation’s largest urological healthcare management company
Latest:
Germline testing study’s implications for veteran access to prostate cancer treatments"[Veterans] may be missing out on potentially life-saving treatments, and their family might also be missing out on some benefits as well," says Daniel Kwon, MD.
Latest:
Future Directions for Imaging and Biopsy in Prostate CancerThe panel offers key takeaways on the evolving landscape for imaging and biopsy in prostate cancer, highlighting the role for fusion-guided biopsy in the diagnosis and management of prostate cancer.
Latest:
Radical nephrectomy before or after systemic therapy for mRCCRecent research has revived the controversy regarding the role of cytoreductive nephrectomy in this setting.
Latest:
How text messaging can be a valuable tool for your practiceHere are seven ways texting can improve healthcare revenue and decrease costs.
Latest:
Integrating video visits into urologic training"Now is the time for programs to leverage their existing telehealth platforms and practices for trainee education while continuing to serve patients," the authors write.
Latest:
Nivolumab plus cabozantinib extends treatment-free survival vs sunitinib in aRCC“Over the 4-year period since first-line protocol therapy initiation, [patients treated with] nivolumab plus cabozantinib achieved a 1.5-times longer mean TFS vs sunitinib," says Charlene Mantia, MD.
Latest:
Online reviews are crucial to maintaining a thriving health care practiceIndependent health care practices rely on online ratings and reviews to attract new patients and establish themselves as leading, recognizable providers in their community.
Latest:
Managing your online reputation in health careWhile online reviews are critical in any industry, patient expectations are simply different when it comes to health care.
Latest:
Neoadjuvant chemoimmunotherapy combo shows promise in UTUCThe phase 2 study explored the combination of the PD-1 inhibitor toripalimab and chemotherapy as neoadjuvant treatment for patients with upper tract urothelial carcinoma.
Latest:
Register Today! UH Urology Institute’s Fall SymposiumsUniversity Hospitals Urology Institute is excited to announce that this coming fall, the department is hosting 2 educational courses in cutting-edge urologic specialties: female sexual health and gender care.
Latest:
Allina Health Cancer Institute 2022 Symposium reimagines cancer careThe symposium brings together clinicians devoted to solving the disease of cancer and the many challenges associated with it.
Latest:
The role of surgery continues to evolve in seminoma"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.
Latest:
Letter: Declassifying Gleason 6 as a cancer would do more harm than good"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.
Latest:
Abiraterone-based triplet boosts survival in de novo mCSPCFindings from the PEACE-1 trial published in the Lancet showed that adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved overall survival in patients with de novo metastatic castration-sensitive prostate cancer.
Latest:
Why favor high intensity focused ultrasound for treating localized prostate cancer?"HIFU allows us to treat where we want and not where we don’t," writes Jennifer Linehan, MD.
Latest:
Smaller medical practices increasingly targeted for cyber attacksPatient data is so valuable — and smaller providers are more vulnerable — that hackers are increasingly targeting physician groups.
Latest:
The aging surgeon: A geriatrician's perspective"We all need to revisit meaningful methods for ongoing assurance of competency specific to our fields of medicine and surgery across the physician career span," writes Hal H. Atkinson, MD, MS.
Latest:
Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBCPanelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and urologists to collaboratively prepare for successful patient outcomes across different markets, while also identifying necessary educational resources and highlighting adverse events that require attention in preparation for product launches.
Latest:
Novel intravesical drug delivery systems explored in bladder cancer"TAR-200 is a sort of a pretzel device. It's a novel drug delivery mechanism that's placed inside the bladder for sustained release of gemcitabine," explains Siamak Daneshmand, MD.
Latest:
Expert advice on improving interactions with difficult patients“Patients will never change, and demanding family members will never change. The solution to the problem is to manage the way we think about them,” writes Joan Naidorf, DO.
Latest:
BCG-unresponsive NMIBC: Current evidence and optionsMultiple investigational agents have been developed and are being studied.
Latest:
Eric Li, MD, on PSMA-PET imaging in men with low PSA levels"We found that almost half of them had suspicious findings as defined by the radiologist, but also that the positivity rate for PSAs below 0.5 were around 35%," says Eric Li, MD.
Latest:
Malpractice Consult: What to know about closing arguments"All the components of the trial are designed to try to ensure that when the jurors depart for the deliberation room, they are inclined to find for the attorney’s side in the case," writes Austin Richards, Esq.
Latest:
Future Directions for the Management of Advanced Prostate CancerBobby Liaw, MD; Vivek K. Narayan, MD, MS; Ashley E. Ross, MD, PhD; and Neal Shore, MD, FACS, provide closing thoughts and advice for the optimal management of advanced prostate cancer.
